Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Hepatocyte, Liver
DISEASE(S): Non-alcoholic Steatohepatitis
SUBMITTER: Xu Cheng
LAB HEAD: Hongliang Li
PROVIDER: PXD018214 | Pride | 2022-08-30
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
P180088_B_AS1.raw | Raw | |||
P180088_B_AS2.raw | Raw | |||
P180088_B_AS3.raw | Raw | |||
P180088_B_PA1.raw | Raw | |||
P180088_B_PA2.raw | Raw |
Items per page: 5 1 - 5 of 13 |
Jian Chongshu C Fu Jiajun J Cheng Xu X Shen Li-Jun LJ Ji Yan-Xiao YX Wang Xiaoming X Pan Shan S Tian Han H Tian Song S Liao Rufang R Song Kehan K Wang Hai-Ping HP Zhang Xin X Wang Yibin Y Huang Zan Z She Zhi-Gang ZG Zhang Xiao-Jing XJ Zhu Lihua L Li Hongliang H
Cell metabolism 20200501 5
Nonalcoholic steatohepatitis (NASH) is becoming one of the leading causes of hepatocellular carcinoma (HCC). Sorafenib is the only first-line therapy for advanced HCC despite its serious adverse effects. Here, we report that at an equivalent of approximately one-tenth the clinical dose for HCC, sorafenib treatment effectively prevents the progression of NASH in both mice and monkeys without any observed significant adverse events. Mechanistically, sorafenib's benefit in NASH is independent of it ...[more]